The Role of Antibodies in Tuberculosis Diagnosis, Prophylaxis and Therapy: a Review from the ESGMYC Study Group

Overview

Journal Eur Respir Rev

Specialty Pulmonary Medicine

Date 2022 Mar 10

PMID 35264411

Authors

Solomon Tibebu Melkie

Lilibeth Arias

Chiara Farroni

Mateja Jankovic Makek

Delia Goletti

Cristina Vilaplana

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is still responsible for the deaths of >1 million people yearly worldwide, and therefore its correct diagnosis is one of the key components of any TB eradication programme. However, current TB diagnostic tests have many limitations, and improved diagnostic accuracy is urgently needed. To improve the diagnostic performance of traditional serology, a combination of different (MTB) antigens and different antibody isotypes has been suggested, with some showing promising performance for the diagnosis of active TB. Given the incomplete protection conferred by bacille Calmette-Guérin (BCG) vaccination against adult pulmonary TB, efforts to discover novel TB vaccines are ongoing. Efficacy studies from advanced TB vaccines designed to stimulate cell-mediated immunity failed to show protection, suggesting that they may not be sufficient and warranting the need for other types of immunity. The role of antibodies as tools for TB therapy, TB diagnosis and TB vaccine design is discussed. Finally, we propose that the inclusion of antibody-based TB vaccines in current clinical trials may be advisable to improve protection.

Citing Articles

Advances in tuberculosis biomarkers: unravelling risk factors, active disease and treatment success.

Schildkraut J, Kohler N, Lange C, Duarte R, Gillespie S Breathe (Sheff). 2024; 20(3):240003.

PMID: 39660087 PMC: 11629168. DOI: 10.1183/20734735.0003-2024.

ELISA-R: an R-based method for robust ELISA data analysis.

Dutt T, Spencer J, Karger B, Fox A, Obregon-Henao A, Podell B Front Immunol. 2024; 15:1427526.

PMID: 39416778 PMC: 11479990. DOI: 10.3389/fimmu.2024.1427526.

Tuberculosis Diagnosis: Current, Ongoing, and Future Approaches.

Bartolomeu-Goncalves G, Souza J, Fernandes B, Spoladori L, Correia G, Castro I Diseases. 2024; 12(9).

PMID: 39329871 PMC: 11430992. DOI: 10.3390/diseases12090202.

Integrating pathogen- and host-derived blood biomarkers for enhanced tuberculosis diagnosis: a comprehensive review.

Li Z, Hu Y, Wang W, Zou F, Yang J, Gao W Front Immunol. 2024; 15:1438989.

PMID: 39185416 PMC: 11341448. DOI: 10.3389/fimmu.2024.1438989.

Antibodies as clinical tools for tuberculosis.

McIntyre S, Warner J, Rush C, Vanderven H Front Immunol. 2024; 14:1278947.

PMID: 38162666 PMC: 10755875. DOI: 10.3389/fimmu.2023.1278947.

References

Baumann R, Kaempfer S, Chegou N, Nene N, Veenstra H, Spallek R . Serodiagnostic markers for the prediction of the outcome of intensive phase tuberculosis therapy. Tuberculosis (Edinb). 2012; 93(2):239-45. DOI: 10.1016/j.tube.2012.09.003. View

Burbelo P, Keller J, Wagner J, Klimavicz J, Bayat A, Rhodes C . Serological diagnosis of pulmonary Mycobacterium tuberculosis infection by LIPS using a multiple antigen mixture. BMC Microbiol. 2015; 15:205. PMC: 4599810. DOI: 10.1186/s12866-015-0545-y. View

Parra M, Pickett T, Delogu G, Dheenadhayalan V, Debrie A, Locht C . The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun. 2004; 72(12):6799-805. PMC: 529156. DOI: 10.1128/IAI.72.12.6799-6805.2004. View

Bretl D, He H, Demetriadou C, White M, Penoske R, Salzman N . MprA and DosR coregulate a Mycobacterium tuberculosis virulence operon encoding Rv1813c and Rv1812c. Infect Immun. 2012; 80(9):3018-33. PMC: 3418728. DOI: 10.1128/IAI.00520-12. View

Goletti D, Lee M, Wang J, Walter N, Ottenhoff T . Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. Respirology. 2018; 23(5):455-466. DOI: 10.1111/resp.13272. View

Tameris M, Hatherill M, Landry B, Scriba T, Snowden M, Lockhart S . Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013; 381(9871):1021-8. PMC: 5424647. DOI: 10.1016/S0140-6736(13)60177-4. View

Maekura R, Kitada S, Osada-Oka M, Tateishi Y, Ozeki Y, Fujicawa T . Serum antibody profiles in individuals with latent Mycobacterium tuberculosis infection. Microbiol Immunol. 2019; 63(3-4):130-138. PMC: 6767593. DOI: 10.1111/1348-0421.12674. View

Balu S, Reljic R, Lewis M, Pleass R, McIntosh R, van Kooten C . A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol. 2011; 186(5):3113-9. PMC: 3115510. DOI: 10.4049/jimmunol.1003189. View

Buch M, Smolen J, Betteridge N, Breedveld F, Burmester G, Dorner T . Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70(6):909-20. PMC: 3086093. DOI: 10.1136/ard.2010.144998. View

10.

Azhar G . DOTS for TB relapse in India: A systematic review. Lung India. 2012; 29(2):147-53. PMC: 3354489. DOI: 10.4103/0970-2113.95320. View

11.

Khaliq A, Ravindran R, Hussainy S, Krishnan V, Ambreen A, Yusuf N . Field evaluation of a blood based test for active tuberculosis in endemic settings. PLoS One. 2017; 12(4):e0173359. PMC: 5381859. DOI: 10.1371/journal.pone.0173359. View

12.

Wahid R, Zafar S, McArthur M, Pasetti M, Levine M, Sztein M . Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B. Clin Vaccine Immunol. 2014; 21(3):427-34. PMC: 3957674. DOI: 10.1128/CVI.00786-13. View

13.

Kumarasamy N, Poongulali S, Beulah F, Akite E, Ayuk L, Bollaerts A . Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial. Medicine (Baltimore). 2018; 97(45):e13120. PMC: 6250513. DOI: 10.1097/MD.0000000000013120. View

14.

Imaz M, Zerbini E . Antibody response to culture filtrate antigens of Mycobacterium tuberculosis during and after treatment of tuberculosis patients. Int J Tuberc Lung Dis. 2000; 4(6):562-9. View

15.

Hoft D, Kemp E, Marinaro M, Cruz O, Kiyono H, McGhee J . A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination. J Lab Clin Med. 1999; 134(3):244-52. DOI: 10.1016/s0022-2143(99)90204-4. View

16.

Wilkie M, Satti I, Minhinnick A, Harris S, Riste M, Ramon R . A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults. Vaccine. 2019; 38(4):779-789. PMC: 6985898. DOI: 10.1016/j.vaccine.2019.10.102. View

17.

Kapopoulou A, Lew J, Cole S . The MycoBrowser portal: a comprehensive and manually annotated resource for mycobacterial genomes. Tuberculosis (Edinb). 2010; 91(1):8-13. DOI: 10.1016/j.tube.2010.09.006. View

18.

Abraham P, Devalraju K, Jha V, Valluri V, Mukhopadhyay S . PPE17 (Rv1168c) protein of Mycobacterium tuberculosis detects individuals with latent TB infection. PLoS One. 2018; 13(11):e0207787. PMC: 6261109. DOI: 10.1371/journal.pone.0207787. View

19.

Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, Lauria F . IP-10 detection in urine is associated with lung diseases. BMC Infect Dis. 2010; 10:333. PMC: 2995466. DOI: 10.1186/1471-2334-10-333. View

20.

Tran A, Kim M, Reljic R . Emerging Themes for the Role of Antibodies in Tuberculosis. Immune Netw. 2019; 19(4):e24. PMC: 6722270. DOI: 10.4110/in.2019.19.e24. View